All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for PHRMA · Represents country's leading pharmaceutical research and biotechnology companies

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Apr 21, 2025

Official filing document

Bills named in this filing 2

HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
S 832
EPIC Act of 2025

Lobbying activity 5

Medicare/Medicaid

General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. IPI drug pricing proposal, Medicare Rebate Rule. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832.

Health Issues

General education about policies impacting pharmaceutical development, approval and reimbursement; Non-interference. Rebates for Medicare Part D. Importation. 340B Program. Drug pricing legislation, Medicare rebate reform, and proposals to impose "most favored nation" pricing on Medicare Part B and D. "Inflation Reduction Act of 2022" (PL 117-169). Pharmacy benefit manager reform proposals. H.R. 1492 and S. 832.

Budget/Appropriations

Issues related to pharmaceutical development; Policies impacting Medicare Part D; Part B and 340 B programs.

Defense

Issues related to pharmaceutical manufacturing and development.

Trade (domestic/foreign)

IP Protections related to trade agreements; trade policies impacting pharmaceutical development. Legislative proposals related to WTO TRIPS Waiver.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.